Table 3 Clinical trials of CAR-T cells targeting non-CD19 antigens in China
Target Antigen | Disease | CAR | Vector | NCT no. |
|---|---|---|---|---|
CD20 | Lymphoma | 4-1BB-CD3ζ | LV | NCT01735604 |
CD20 | B cell lymphoma | CD3ζ and CD28 | RV | NCT02965157 |
CD20 | B cell malignancies | NA | NA | NCT02710149 |
CD22 | CD19-refractory or resistant lymphoma | TCRζ, 4-1BB | RV | NCT02721407 |
CD22 | Recurrent or refractory B cell malignancy | NA | NA | NCT02794961 |
CD22 | B cell malignancies | NA | NA | NCT02935153 |
CD30 | Lymphoma | NA | LV | NCT02274584 |
CD30 | HL, NHL | NA | NA | NCT02259556 |
CD30 | Lymphocyte malignancies | NA | NA | NCT02958410 |
CD33 | AML | 4-1BB-CD3ζ | RV | NCT01864902 |
CD33 | AML | NA | NA | NCT02799680 |
CD33 | Myeloid malignancies | NA | NA | NCT02958397 |
BCMA | B cell malignancies | NA | NA | NCT02954445 |
BCMA | Multiple myeloma | TCRζ, 4-1-BB | RV | NCT03093168 |
CD123 | Leukemia | NA | NA | NCT02937103 |
CD123 | AML recurred after allo-HSCT | 41BB-CD3ζ | NA | NCT03114670 |
CD138 | Multiple myeloma | 4-1BB-CD3ζ | RV | NCT01886976 |
CD138/BCMA | Multiple myeloma | NA | NA | NCT03196414 |
Lewis-Y | Myeloid malignancies | NA | NA | NCT02958384 |